3,5-dibromo-2-hydroxy-N-hydroxymethyl-benzamide | 51028-68-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dibromo-2-hydroxy-N-hydroxymethyl-benzamide
• 英文别名: N-Hydroxymethyl-3,5-dibromosalicylamid；3,5-dibromo-2-hydroxy-N-(hydroxymethyl)benzamide
• CAS: 51028-68-3
• 化学式: C₈H₇Br₂NO₃
• 分子量: 324.956
• InChiKey: KBEFRCFONNISJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-dibromo-2-hydroxy-N-hydroxymethyl-benzamide 、 糖精 生成 3,5-dibromo-2-hydroxy-N-(1,1,3-trioxo-1,3-dihydro-1λ⁶-benzo[d]isothiazol-2-ylmethyl)-benzamide
  参考文献：
  名称：

  Singh; Vijjan; Jetly, Journal of the Indian Chemical Society, 1973, vol. 50, # 5, p. 347 - 349

  摘要：

  DOI：

文献信息

• Amino-methyl substituted tetracycline compounds
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：EP2301534A1

  公开（公告）日：2011-03-30

  1. A tetracycline compound having the following formula: wherein: J5 and J6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, sulfonyl, acyl, substituted carbonyl or substituted thiocarbonyl, or linked to form a ring; J7 and J8 are each alkyl, halogen, or hydrogen; and R7 is hydrogen, or pharmaceutically acceptable salts thereof.

  1.具有下式的四环素化合物： 其中 J5和J6各自独立地是氢、烷基、烯基、炔基、芳基、磺酰基、酰基、取代的羰基或取代的硫代羰基，或连接成环； J7 和 J8 分别是烷基、卤素或氢；以及 R7 为氢、 或其药学上可接受的盐。
• 9-Aminomethyl Substituted Minocycline Compounds
  申请人：Nelson Mark L.

  公开号：US20100113400A1

  公开（公告）日：2010-05-06

  The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
• 9-AMINOMETHYL SUBSTITUTED MINOCYCLINE COMPOUNDS
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：US20140309199A1

  公开（公告）日：2014-10-16

  The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
• US7326696B2
  申请人：——

  公开号：US7326696B2

  公开（公告）日：2008-02-05
• US7553828B2
  申请人：——

  公开号：US7553828B2

  公开（公告）日：2009-06-30